Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2021-10-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
NCT05044091
HRD and Resistance to PAPPi in EOC Patients
NCT05310370
An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy
NCT05255861
The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
NCT06242392
Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario
NCT06836219
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female subjects are older than 18 years;
3. ECOG(Eastern Cooperative Oncology Group) physical status score is 0-2;
4. Life expectancy≥3 months;
5. Histologically confirmed FIGO(International Federation of Gynecology and Obstetrics ) III/IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; Participants must have high-grade serous histology
Exclusion Criteria
2. The subjects had other malignant diseases in past 2 years, except skin squamous cell carcinoma, basal-like carcinoma, breast intraductal carcinoma in situ, or cervical carcinoma in situ;
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiaoxiang Chen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaoxiang Chen
Academic secretary of gynecological oncology Committee of Jiangsu anti cancer association
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaoxiang Chen Chen, MD,PhD
Role: STUDY_CHAIR
Jiangsu Cancer Institute & Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xiaoxiang Chen
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Xiaoxiang Chen, MD,PhD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiaoxiang Chen
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JiangsuCIH011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.